Navigation Links
Boston Scientific Launches Charger™ PTA Balloon Catheter

NATICK, Mass., Dec. 12, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of its Charger™ PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty (PTA) balloon catheter designed for a wide range of peripheral angioplasty procedures.  The Charger PTA Balloon Catheter is Boston Scientific's third new peripheral balloon catheter introduced in 2011 and strengthens the Company's position as a global leader in peripheral angioplasty balloons. 

The Charger PTA Balloon Catheter is designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries.  It features high rated burst pressures (up to 20 ATM for selected sizes), rapid deflation, and a low lesion entry profile. 

"The Charger PTA Balloon Catheter is designed to deliver results in both routine and challenging cases," said Jeff Mirviss, President of Boston Scientific's Peripheral Interventions Division.  "With a low profile and tapered tip, it is engineered to provide excellent push without sacrificing track.  The Charger PTA Balloon Catheter complements our growing portfolio of interventional devices for peripheral vasculature procedures."

The Charger PTA Balloon Catheter is compatible with a 6 Fr sheath for 10x80 mm balloons and is available in a broad range of sizes including 3-12 mm diameters and 20-200 mm lengths on 75 or 135 cm shafts.

For more information, please visit:

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit:  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, market share, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.



Eric Olson
336-293-4393 (office)
Media Relations
Boston Scientific Corporation                   

Sean Findlen
617-520-7268  (office)
Media Relations
Weber Shandwick                     

Sean Wirtjes
508-652-5305 (office)
Investor Relations
Boston Scientific Corporation









SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Receives FDA Approval for New Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System
2. Boston Scientific Introduces Industry-Leading ICD and CRT-D Device Warranties
3. Boston Scientifics WATCHMAN® Device Implanted in First Patients in Latin America
4. Boston Scientific Applauds Introduction of Patient Access to Medical Innovation Act
5. Boston Scientific SYNERGY™ Stent Demonstrates Comparable Safety and Effectiveness Outcomes Versus PROMUS Element™ Platinum Chromium Stent
6. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
7. Boston Scientific CRE™ Wireguided Balloon Dilator CE Marked for Expanded Indication
8. Boston Scientific Carotid WALLSTENT® Found Safe in Study of High Surgical Risk Patients in Routine Clinical Practice
9. Boston Scientifics PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions
10. Boston Scientific Announces Schedule of Events at TCT Scientific Symposium
11. Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
Breaking Medicine Technology:
(Date:11/28/2015)... Aliso Viejo, CA (PRWEB) , ... November 28, 2015 , ... ... 30 new fully customizable media panels to choose from, the possibilities are endless. Users ... angle, and more. With the ProPanel: Pulse masking effects, users are sure to get ...
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... were," said an inventor from Hillside, N.J. "Many people catch diseases simply from ... that individuals will always be protected from germs." , He developed the patent-pending ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
Breaking Medicine News(10 mins):